What is Zacks Research’s Estimate for AXSM FY2024 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at Zacks Research reduced their FY2024 earnings estimates for shares of Axsome Therapeutics in a research report issued to clients and investors on Tuesday, January 7th. Zacks Research analyst R. Department now expects that the company will post earnings of ($5.42) per share for the year, down from their previous estimate of ($5.32). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.60) per share. Zacks Research also issued estimates for Axsome Therapeutics’ Q4 2024 earnings at ($1.75) EPS, Q1 2025 earnings at ($1.71) EPS, Q2 2025 earnings at ($1.60) EPS, Q3 2025 earnings at ($1.16) EPS, Q4 2025 earnings at ($1.29) EPS, FY2025 earnings at ($5.77) EPS, Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at $0.11 EPS, Q4 2026 earnings at $0.06 EPS and FY2026 earnings at ($0.67) EPS.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. The company had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same period in the prior year, the firm earned ($1.32) earnings per share.

A number of other brokerages have also issued reports on AXSM. Needham & Company LLC reiterated a “buy” rating and set a $133.00 price target on shares of Axsome Therapeutics in a research note on Monday, January 6th. HC Wainwright restated a “buy” rating on shares of Axsome Therapeutics in a research note on Tuesday, December 31st. Cantor Fitzgerald restated an “overweight” rating and set a $121.00 target price on shares of Axsome Therapeutics in a research note on Thursday, December 12th. Robert W. Baird upped their target price on shares of Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, Mizuho cut their target price on shares of Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating on the stock in a research note on Tuesday, December 31st. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $127.29.

Axsome Therapeutics Stock Down 3.1 %

Shares of NASDAQ:AXSM opened at $80.05 on Thursday. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. The firm has a market capitalization of $3.88 billion, a PE ratio of -12.26 and a beta of 1.04. The firm’s 50-day moving average is $92.35 and its two-hundred day moving average is $88.99. Axsome Therapeutics has a 1 year low of $64.11 and a 1 year high of $105.00.

Hedge Funds Weigh In On Axsome Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in AXSM. FMR LLC boosted its holdings in shares of Axsome Therapeutics by 20.6% in the third quarter. FMR LLC now owns 1,088,087 shares of the company’s stock valued at $97,786,000 after acquiring an additional 185,951 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Axsome Therapeutics by 2.7% in the third quarter. Geode Capital Management LLC now owns 908,459 shares of the company’s stock valued at $81,659,000 after acquiring an additional 23,564 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Axsome Therapeutics by 1.1% in the third quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock valued at $66,750,000 after acquiring an additional 8,125 shares during the period. Millennium Management LLC boosted its holdings in shares of Axsome Therapeutics by 1.4% in the second quarter. Millennium Management LLC now owns 739,819 shares of the company’s stock valued at $59,555,000 after acquiring an additional 10,401 shares during the period. Finally, Hood River Capital Management LLC boosted its holdings in shares of Axsome Therapeutics by 5.4% in the second quarter. Hood River Capital Management LLC now owns 549,066 shares of the company’s stock valued at $44,200,000 after acquiring an additional 28,316 shares during the period. 81.49% of the stock is owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.